



## Bright Minds Biosciences Appoints New Board Member and Expands Leadership Team

**Additions of industry veterans, Dr. Emer Leahy to the Board of Directors and Dr. Tom Lategan as Vice President of Regulatory Affairs, position the Company to advance drug development programs**

VANCOUVER, British Columbia, June 14, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced a new appointment to its Board of Directors and one addition to its leadership team:

- Emer Leahy, PhD, MBA, will join Bright Minds' Board of Directors.
- Tom Lategan, PhD, Vice President of Regulatory Affairs, will manage Bright Minds' regulatory and medical affairs.

"We are pleased to welcome Dr. Emer Leahy to the Bright Minds Biosciences Board. Her deep experience and track record of success in business development for pharmaceutical and biotechnology companies will help guide our drug development plans. We are also excited about the addition of Dr. Tom Lategan, whose extensive background in regulatory affairs will be an important asset to our team. We look forward to their insights as we continue to advance our programs to bring improved and targeted therapeutics to the patients who can benefit," stated Ian McDonald, Chief Executive Officer of Bright Minds.

Emer Leahy, PhD, MBA, has over 30 years of experience in drug discovery, as well as clinical and business development for pharmaceutical and biotechnology companies. Dr. Leahy brings a wealth of knowledge in technology assessment, licensing, mergers and acquisitions, and strategic planning. Currently, Dr. Leahy serves as the CEO of PsychoGenics, Inc., a profitable preclinical CNS service company, and PGI Drug Discovery, LLC, a company engaged in psychiatric drug discovery. Previously, she served on the Emerging Companies Section Governing Board for the Board of Directors of the Biotechnology Industry Organization ("BIO"), and currently serves on the Board of Directors of Intensity Therapeutics, the Business Review Board for the Alzheimer's Drug Discovery Foundation, and the Scientific Advisory Board of the International Rett Syndrome Foundation. She received her PhD in Neuropharmacology from University College Dublin, Ireland, and her MBA from Columbia University.

Tom Lategan, PhD, has more than 20 years of experience in the pharmaceutical industry, across large-capitalization and start-up companies. Most recently, Dr. Lategan served as the Vice President of Regulatory Affairs for Banner Life Sciences. Prior to that, he served as the Vice President of Regulatory Affairs and Head of Clinical Operations at NeurAxon, Inc. He previously held positions of increasing responsibility in regulatory and medical affairs with Actelion, The Medicines Company and Hoffman-La Roche. He received a D.Phil from Oxford University and a B.Sc. in pharmacology from Aberdeen University in Scotland.

### About Bright Minds

Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors. The Company is developing targeted therapies with the potential to improve the treatment of mental health and neurological disorders through the use of serotonergic compounds leveraging its world class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.

### Forward-Looking Statements

This news release contains forward-looking statements, including statements regarding the date of listing of the Shares and the advancement of the Company's drug development program, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, and which are described in the Company's public filings available under its profile at [www.sedar.com](http://www.sedar.com). The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking

statements contained in this news release are made as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as required by Canadian securities laws.

**Investor Contact:**

Judy DiClemente

[jdiclemente@insitecony.com](mailto:jdiclemente@insitecony.com)

T: 212-452-2793